Competact (pioglitazone;metformin)
- Region
- 🇪🇺 EU
- Active substance
- pioglitazone;metformin
- Company
- CHEPLAPHARM Arzneimittel GmbH
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Fri 28 Jul 2006
- Application
- EMEA/H/C/000655
- ATC
- A10BD05
- Official record
- www.ema.europa.eu
Indication
Competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Glubrava Withdrawn · Takeda Pharma A/S
Follow Competact
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.